Long-Acting Injectable Cabotegravir for HIV Prevention: What do we know and need to know about the risks and consequences of cabotegravir resistance?
This article from The Science of Prevention summarizes what is known about cabotegravir (CAB) pharmacokinetics, activity, and emergence of resistance from in vitro, macaque and clinical studies, and evaluates the risk of resistance from CAB for PrEP with on-time injections and after CAB for PrEP discontinuation.
Integrated Study Dashboard
This dashboard, produced under the BioPIC project, reflects all currently known activities relating to implementation research, modelling, clinical trials, open label extensions, and landscaping for new late stage biomedical HIV PrEP options, including cabotegravir for PrEP and the dapivirine vaginal ring. To update or add any activities missing from the dashboard, or if you have…
Deep Dive Review of Modelling Long Acting PrEP Meeting Summary
In March 2023, the Bill and Melinda Gates Foundation convened modellers looking into the impact, costs, and/or cost effectiveness of cabotegravir (CAB) for PrEP in low and middle income countries. This meeting summary provides an overview of 11 models as well as key insights emerging from the models and knowledge gaps.
Report: Formative research on CAB for PrEP in Eswatini
The goal of this study was to assess access needs, product acceptability, values, and preferences for the new PrEP method. This activity was a collaboration between EpiC and MOSAIC, and included adolescent girls and young women, men who have sex with men, people who inject drugs, female sex workers, pregnant and breastfeeding populations, and transgender…
Shaping and Strengthening Markets for a New Era of Choice-based HIV/SRH Programming: Lessons from HIV & FP product introduction Report
This report was from the BioPIC Think Tank, Shaping and Strengthening Markets for a New Era of Choice-based HIV/SRH Programming: Lessons from HIV & FP product introduction. As new HIV prevention products move closer to entering the market, there is an opportunity to design choice-based programs that apply lessons and successes from HIV and FP…
Safety and Efficacy of Long-Acting Injectable Cabotegravir as Preexposure Prophylaxis To Prevent HIV Acquisition
This journal article from AIDS reviewed existing evidence to determine the efficacy and safety of CAB for PrEP in order to inform global guidelines.
Shaping and Strengthening Markets for a New Era of Choice-based HIV/SRH Programming: Lessons from HIV & FP product introduction Slides
These slides were featured at the BioPIC Think Tank, Shaping and Strengthening Markets for a New Era of Choice-based HIV/SRH Programming: Lessons from HIV & FP product introduction. As new HIV prevention products move closer to entering the market, there is an opportunity to design choice-based programs that apply lessons and successes from HIV and…
Extended Analysis of HIV Infection in Cisgender Men and Transgender Women Who Have Sex with Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083
This journal article from Antimicrobial Agents and Chemo Therapy shares an extended report on HIV infections that occurred up to 1 year after study unblinding (18 in the CAB arm and 34 in the TDF-FTC arm).
Addressing the Need for a Preexposure Prophylaxis Monitoring and Evaluation Implementation Guide: Experience From Zambia
The HIV care continuum comprises well-defined steps and indicators. In contrast, indicators along the preexposure prophylaxis (PrEP) cascade are still in the early stages of implementation. Monitoring and evaluation (M&E) of PrEP services is critical to optimizing PrEP uptake and adherence during periods of HIV risk. We provide an overview of global indicators for PrEP,…
Guidance: Standard Operating Procedures for Addressing Partner Relationships and Gender-Based Violence in Pre-Exposure Prophylaxis (PrEP) Services
Standard Operating Procedure Guidance Evidence has shown that intimate partner violence (IPV) may act as a barrier to accessing HIV services, including PrEP services. IPV is associated with lower PrEP uptake and adherence and increased PrEP interruption among cisgender women. Although cisgender women have made up the majority of participants in research on PrEP and…